Trials / Active Not Recruiting
Active Not RecruitingNCT07052032
An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients With Seropositive Rheumatoid Arthritis
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- Candid Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.
Detailed description
This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND261 in patients with seropositive rheumatoid arthritis. The study consists of 2 parts: a dose-escalation part and an open-label expansion. Patients will be followed until Week 52.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CND261 | CND261 will be dosed according to the assigned cohort |
Timeline
- Start date
- 2025-06-16
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2025-07-04
- Last updated
- 2026-04-16
Locations
3 sites across 3 countries: Georgia, Moldova, Ukraine
Source: ClinicalTrials.gov record NCT07052032. Inclusion in this directory is not an endorsement.